Urol J:患有前列腺癌且经历雄激素阻断治疗的病人中抑郁与许多风险因素之间的相关性分析

2018-02-23 AlexYang MedSci原创

最近,有研究人员在经历雄激素阻断疗法(ADT)治疗前列腺癌的患者中鉴定了影响抑郁的因素。研究包括了那些拜访精神病门诊的患有前列腺癌的患者,并且他们都经历了ADT且伴随着抑郁症状。为了评估抑郁症状,研究人员使用了白氏抑郁症量表(BDI)。为了鉴定影响抑郁症的风险因素,研究人员进行了单变量和多变量的线性回归分析。研究发现,参与者(n=45)的平均年龄、ADT起始治疗年龄和ADT持续时间、血清睾丸素水平

最近,有研究人员在经历雄激素阻断疗法(ADT)治疗前列腺癌的患者中鉴定了影响抑郁的因素。

研究包括了那些拜访精神病门诊的患有前列腺癌的患者,并且他们都经历了ADT且伴随着抑郁症状。为了评估抑郁症状,研究人员使用了白氏抑郁症量表(BDI)。为了鉴定影响抑郁症的风险因素,研究人员进行了单变量和多变量的线性回归分析。

研究发现,参与者(n=45)的平均年龄、ADT起始治疗年龄和ADT持续时间、血清睾丸素水平和BDI得分分别是73.9 ± 7.9 岁, 72 ± 8.5 岁, 33 ± 31.6个月, 214.9 ± 219.5 ng/dL 和18 ± 13.5 分。雄激素依赖和独立的患者分别为26名和9名病人。其中,雄激素不依赖的8名患者经历了同步放化疗。21名患者使用比卡鲁胺治疗和24名患者使用醋酸亮丙瑞林治疗。在影响BDI得分的临床变量中,ADT药物类型(p<0.001)、血清睾丸素水平(p=0.003)和诊断的年龄(p<0.001)均为显著水平。最后,研究人员指出,诊断工作的加强和合适的治疗抑郁,尤其是那些经历ADT且使用一种LHRH兴奋剂来治疗前列腺癌的患者的抑郁症状的变化具有低的睾丸素水平或者起始ADT时年龄更大。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641268, encodeId=6aa8164126840, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Nov 18 07:02:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710120, encodeId=1e681e1012012, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Apr 24 11:02:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837462, encodeId=0f5a183e46276, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 13 18:02:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291191, encodeId=f712291191a8, content=学习了.分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Mon Feb 26 23:03:43 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290880, encodeId=22f629088026, content=-谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Feb 25 23:13:14 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385154, encodeId=e539138515438, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523600, encodeId=dc2f152360086, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641268, encodeId=6aa8164126840, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Nov 18 07:02:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710120, encodeId=1e681e1012012, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Apr 24 11:02:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837462, encodeId=0f5a183e46276, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 13 18:02:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291191, encodeId=f712291191a8, content=学习了.分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Mon Feb 26 23:03:43 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290880, encodeId=22f629088026, content=-谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Feb 25 23:13:14 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385154, encodeId=e539138515438, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523600, encodeId=dc2f152360086, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1641268, encodeId=6aa8164126840, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Nov 18 07:02:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710120, encodeId=1e681e1012012, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Apr 24 11:02:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837462, encodeId=0f5a183e46276, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 13 18:02:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291191, encodeId=f712291191a8, content=学习了.分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Mon Feb 26 23:03:43 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290880, encodeId=22f629088026, content=-谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Feb 25 23:13:14 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385154, encodeId=e539138515438, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523600, encodeId=dc2f152360086, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1641268, encodeId=6aa8164126840, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Nov 18 07:02:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710120, encodeId=1e681e1012012, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Apr 24 11:02:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837462, encodeId=0f5a183e46276, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 13 18:02:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291191, encodeId=f712291191a8, content=学习了.分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Mon Feb 26 23:03:43 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290880, encodeId=22f629088026, content=-谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Feb 25 23:13:14 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385154, encodeId=e539138515438, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523600, encodeId=dc2f152360086, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
    2018-02-26 梦想起航ing

    学习了.分享.谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1641268, encodeId=6aa8164126840, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Nov 18 07:02:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710120, encodeId=1e681e1012012, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Apr 24 11:02:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837462, encodeId=0f5a183e46276, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 13 18:02:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291191, encodeId=f712291191a8, content=学习了.分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Mon Feb 26 23:03:43 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290880, encodeId=22f629088026, content=-谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Feb 25 23:13:14 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385154, encodeId=e539138515438, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523600, encodeId=dc2f152360086, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
    2018-02-25 清风拂面

    -谢谢分享学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1641268, encodeId=6aa8164126840, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Nov 18 07:02:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710120, encodeId=1e681e1012012, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Apr 24 11:02:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837462, encodeId=0f5a183e46276, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 13 18:02:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291191, encodeId=f712291191a8, content=学习了.分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Mon Feb 26 23:03:43 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290880, encodeId=22f629088026, content=-谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Feb 25 23:13:14 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385154, encodeId=e539138515438, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523600, encodeId=dc2f152360086, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1641268, encodeId=6aa8164126840, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sun Nov 18 07:02:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710120, encodeId=1e681e1012012, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Apr 24 11:02:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837462, encodeId=0f5a183e46276, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Sep 13 18:02:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291191, encodeId=f712291191a8, content=学习了.分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Mon Feb 26 23:03:43 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290880, encodeId=22f629088026, content=-谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Feb 25 23:13:14 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385154, encodeId=e539138515438, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523600, encodeId=dc2f152360086, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Feb 25 11:02:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]

相关资讯

CLIN CANCER RES:恩杂鲁胺对卡巴他赛药代动力学的影响

在转移性去势抵抗前列腺癌的临床研究中,目前正在探索紫杉烷类联合AR靶向药物,即恩杂鲁胺和阿比特龙的治疗效果是否可以得到增强。因为恩杂鲁胺可以诱导CYP3A4酶而紫杉烷类药物由这种酶代谢,需要研究其潜在的药物之间的相互作用。CLIN CANCER RES近期发表了一篇文章研究这一问题。

Prostate:血浆中循环microRNAs是前列腺癌早期检测的潜在生物标记

microRNAs(miRNAs)与前列腺癌(PC)风险相关,然而,它们作为一个PC筛选生物标记的作用还未被鉴定。最近,有研究人员探究了是否在那些经历了前列腺癌针刺活检的男性中,血浆中的循环miRNAs能够成为PC早期检测潜在的生物标记。研究包括了134名男性,年龄在46-86岁之间,其中66名男性具有PC诊断结果(案例),8名男性没有PC诊断结果但是具有不典型病变,60名男性没有PC诊断结果(对

Brit J Cancer:多烯紫杉醇结合Aneustat治疗能够强烈的抑制晚期前列腺癌的转移

多烯紫杉醇是治疗晚期前列腺癌(PCa)的首选药物,并且只有较低水平的治疗效果。之前研究人员表明,利用LTL-313H肾包膜来源的转移性PCa异种种植模型,且利用一种多烯紫杉醇结合Aneustat(OMN54),能够明显的增强肿瘤生长抑制作用。最近,有研究人员调查了多烯紫杉醇+Aneustat组合疗法对转移的影响。研究人员发现,多烯紫杉醇+Aneustat组合疗法能够显著的抑制C4-2细胞迁移和LT

Oncol Rep: PARP1-siRNA能够抑制人类前列腺癌细胞的生长和恶化

Poly聚合酶(PARP)抑制剂,比如奥拉帕尼或者rucaparib,在BRCA1/2缺陷型肿瘤中展现出了治疗活性。然而,虽然PARP抑制剂(PARPi)主要调控PARP的激活而不是表达,是否PARP特异性针对的小干扰RNA(siRNA)与PARRPi具有与相同的功能仍旧未知。最近,有研究人员阐释了不考虑BRCA1/2的变异,PARP-1能够减少前列腺癌(PCa)细胞的恶化。PARP1的沉默能够显

FDA批准强生前列腺癌新疗法 可延长生存期超2年

近日,美国食品药品监督管理局(FDA)宣布,批准强生(Johnson & Johnson)旗下的杨森(Janssen)公司下一代雄激素受体抑制剂Erleada(apalutamide),用于治疗非转移性去势抵抗性前列腺癌(NM-CRPC)患者。这些患者虽然在接受激素治疗,但肿瘤仍继续增长。值得一提的是,它是首个经FDA批准的用于非转移性去势抵抗性前列腺癌的疗法。美国国立卫生研究院的国家癌

J Clin Oncol:转移性激素敏感前列腺癌化学激素治疗分析

将多烯紫杉醇加入到雄激素阻断治疗(ADT)中能够显著的增加一些患有转移激素敏感性前列腺癌患者的寿命。最近,有研究人员呈现了CHAARTED(前列腺癌广泛性疾病的化学激素治疗VS雄激素阻断随机试验)试验结果,并且具有更加成熟的跟踪调查且关注肿瘤体积。研究包括了790名患有转移性激素敏感前列腺癌的患者,并且被随机平均分配到接受ADT结合多烯紫杉醇75mg/m2或者只接受ADT治疗的两个小组中。研究发现